Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Portfolio Pulse from
Reviva Pharmaceuticals Holdings, Inc. announced positive results for brilaroxazine in treating schizophrenia, which will be presented at the CNS Summit 2024.
November 06, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Reviva Pharmaceuticals announced positive Phase 3 trial results for brilaroxazine in treating schizophrenia, which will be presented at the CNS Summit 2024.
The announcement of positive Phase 3 trial results is likely to boost investor confidence in Reviva Pharmaceuticals, potentially leading to a short-term increase in stock price. The presentation at a major summit further validates the significance of the findings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100